Many psoriasis patients undertreated for CV risk factors

June 22, 2012
Many psoriasis patients undertreated for CV risk factors
A large proportion of patients with moderate-to-severe plaque psoriasis are underdiagnosed and undertreated for cardiovascular risk factors, according to a study published in the July issue of the Journal of the American Academy of Dermatology.

(HealthDay) -- A large proportion of patients with moderate-to-severe plaque psoriasis are underdiagnosed and undertreated for cardiovascular (CV) risk factors, according to a study published in the July issue of the Journal of the American Academy of Dermatology.

Alexa B. Kimball, M.D., from Harvard Medical School in Boston, and colleagues reviewed the , including glucose, lipid, and , of 2,899 patients with moderate-to-severe psoriasis participating in three phase III ustekinumab trials.

The researchers found that there were significant risk factors in patients with moderate-to-severe psoriasis, with 58.6 and 28.8 percent of patients, respectively, having two or more and three or more CV risk factors. The risk of CV events, based on Framingham risk score, was high for 18.6 percent of patients and intermediate for 12.3 percent of patients. A small proportion of patients with diabetes, hypertension, or hyperlipidemia were undiagnosed at baseline (2.3, 9.1, and 4.9 percent, respectively). A higher proportion were untreated at baseline (19.1, 21.8, and 38.6 percent, respectively), and the proportion achieving the treatment goal was not ideal (36.7, 59.6, and 69.7 percent, respectively).

"In summary, study findings highlight the fact that despite a growing recognition of the association between psoriasis and CV risk, a high proportion of patients with psoriasis severe enough to qualify for clinical trial participation have unrecognized or inadequately treated CV risk factors," the authors write.

Several authors disclosed to the pharmaceutical industry.

Explore further: UVB preferred for treatment of moderate to severe psoriasis

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

UVB preferred for treatment of moderate to severe psoriasis

February 24, 2012

(HealthDay) -- Ultraviolet B (UVB) is preferred by dermatologists for first-line treatment of moderate to severe psoriasis in both healthy male and female patients, according to a study published in the March issue of the ...

Study compares effectiveness of psoriasis treatments

April 20, 2012

(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.

Psoriasis increases risk of diabetes: study

June 18, 2012

Psoriasis is an independent risk for Type 2 Diabetes, according to a new study by researchers with the Perelman School of Medicine at the University of Pennsylvania, with the greatest risk seen in patients with severe psoriasis. ...

Recommended for you

Cellphone data can track infectious diseases

August 20, 2015

Tracking mobile phone data is often associated with privacy issues, but these vast datasets could be the key to understanding how infectious diseases are spread seasonally, according to a study published in the Proceedings ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.